24.8 C
New York
Saturday, June 6, 2026

Tag: press release

InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering

New York, NY, June 05, 2026 (GLOBE NEWSWIRE) -- InterPrivate Investment Partners V, Inc. (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced the closing of its initial public offering of 20,125,000 units, including 2,625,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full, at a price of $10.00 per unit on June 5, 2026. Total gross proceeds from the offering were $201.25 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Re: TriWest IV’s Holdings in Source Energy Services Ltd.

CALGARY, AB, June 5, 2026 /CNW/ - TriWest Capital Partners IV (US), L.P., SES Sand Holdings (Canada) LP, SES Sand Holdings 2 (Canada) LP...

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors it Has Filed a Complaint to Recover Losses Suffered by Purchasers of Verra Mobility Corporation Common...

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Power Metallic Mines Files Amended LIFE Offering Document to include Quebec as an Offering Jurisdiction for previously announced Brokered LIFE Offering for Gross Proceeds...

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, June 5, 2026 /CNW/ - Power...

AURION OBTAINS SECURITYHOLDER APPROVAL FOR PLAN OF ARRANGEMENT WITH AGNICO EAGLE MINES LIMITED

ST. JOHN'S, NL, June 5, 2026 /CNW/ - Aurion Resources Ltd. (TSXV: AU) (OTCQX: AIRRF) ("Aurion") is pleased to announce that, at its special meeting (the...

Vireo Growth Inc. Completes Acquisition of Bridgewell Agribusiness LLC and Plans to Acquire Dispensaries in Nevada and Maryland

Vireo Growth Inc. completes acquisition of Bridgewell Agribusiness LLC and plans to acquire dispensaries in Nevada and Maryland.

Quantinuum Announces Closing of Upsized Initial Public Offering

BROOMFIELD, Colo., June 6, 2026 /PRNewswire/ -- Quantinuum Inc. (Nasdaq: QNT) ("Quantinuum") today announced the closing of its upsized initial public offering of 28,000,000...

TKROBOTS Launches AI Quant Trading Platform With Free Trial Access for New Users

TKROBOTS introduces an AI-powered crypto quantitative trading platform with automated execution, wallet management, daily settlement records, and free trial access for new users.
TKROBOTS introduces an AI-powered crypto quantitative trading platform with automated execution, wallet management, daily settlement records, and free trial access for new users.

Premier Health of America Announces Grant of Management Cease Trade Order

MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health”, or the “Company”) announces that, further to its press release dated June 2, 2026, the Autorité des marchés financiers, as the Company’s principal regulator, has granted a management cease trade order (the “MCTO”) under National Policy 12-203 – Management Cease Trade Orders.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPress release